News / Taiwan / economic_daily
Pei-Er Biomedical Shares Hit Limit Down for Second Day Post-Split
Health Technology · Biotechnology · economic_daily · 2026-09-08
6949
Pei-Er Biomedical faces heavy selling pressure following its 1-for-20 stock split, though signs of stabilization emerge as limit-down sell orders decrease.
What Happened
Post-Split Market Reaction: Pei-Er Biomedical saw its shares hit the daily limit-down for two consecutive sessions following its re-listing on September 7th after a 1-for-20 stock split. Despite the sharp decline to 60.4 TWD, the number of sell orders at the limit price has significantly decreased, suggesting that the initial wave of panic selling is beginning to subside.
Increased Liquidity and Profit-Taking: The stock split, which adjusted the par value from 10 TWD to 0.5 TWD, increased the total share count while maintaining the same total market capitalization. This move significantly lowered the entry barrier per board lot, allowing early shareholders who enjoyed an 88% rally in the month prior to the split to liquidate their positions more easily.
Clinical and Regulatory Progress: The company's primary focus remains its autologous CAR-T therapy, PL001, which has successfully passed the interim analysis of its Phase II clinical trial. Pei-Er is currently working with the Center for Drug Evaluation (CDE) to secure conditional approval under the Regenerative Medicine Act, with a target of obtaining a temporary drug license by late 2024 or early 2025.
Outlook and Investor Sentiment: Market participants are closely monitoring the stock's price action as it attempts to find a bottom following the recent volatility. Future performance will likely hinge on the company's ability to navigate the regulatory pathway for its CAR-T therapy and maintain investor confidence amidst the increased share supply.